A translation inhibitor identified in a Drosophila screen enhances the effect of ionizing radiation and taxol in mammalian models of cancer

DMM Disease Models and Mechanisms

Volumn 5, Issue 3, 2012, Pages 342-350

  Gladstone, Mara ^a   Frederick, Barbara ^b   Zheng, Di ^c,e   Edwards, Anthony ^a,c   Yoon, Petros ^a   Stickel, Stefanie ^a   DeLaney, Tessie ^a   Chan, Daniel C ^c,d   Raben, David ^b,d   Su, Tin Tin ^a,d  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^e TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BOUVARDIN; NC 259968; PACLITAXEL; PROTEIN SYNTHESIS INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CELL DIVISION; CELL PROLIFERATION; CONTROLLED STUDY; DROSOPHILA; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IONIZING RADIATION; MOUSE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; BIOLOGICAL AGENTS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; DROSOPHILA MELANOGASTER; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MICE; MUTATION; NEOPLASMS; PACLITAXEL; PEPTIDES, CYCLIC; PROTEIN BIOSYNTHESIS; RADIATION, IONIZING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

DROSOPHILA MELANOGASTER; MAMMALIA; MUS;

EID: 84860783068     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.008722     Document Type: Article

References (44)

1. Adwankar, M. K., Khandalekar, D. D. and Chitnis, M. P. (1984). Combination chemotherapy of early and advanced murine P388 leukaemia with bouvardin, cisdiamminedichloroplatinum and vincristine. Oncology 41, 370-373. (Pubitemid 14054813)
2. Ahuja, D., Vera, M. D., SirDeshpande, B. V., Morimoto, H., Williams, P. G., Joullie, M. M. and Toogood, P. L. (2000). Inhibition of protein synthesis by didemnin B: how EF- 1alpha mediates inhibition of translocation. Biochemistry 39, 4339-4346. (Pubitemid 30212649)
3. Bordeleau, M. E., Robert, F., Gerard, B., Lindqvist, L., Chen, S. M., Wendel, H. G., Brem, B., Greger, H., Lowe, S. W., Porco, J. A., Jr et al. (2008). Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J. Clin. Invest. 118, 2651-2660. (Pubitemid 351949792)
4. Boscia, R. E., Korbut, T., Holden, S. A., Ara, G. and Teicher, B. A. (1993). Interaction of topoisomerase I inhibitors with radiation in cis-diamminedichloroplatinum(II)-sensitive and -resistant cells in vitro and in the FSAIIC fibrosarcoma in vivo. Int. J. Cancer 53, 118-123. (Pubitemid 23018433)
5. Brodsky, M. H., Nordstrom, W., Tsang, G., Kwan, E., Rubin, G. M. and Abrams, J. M. (2000). Drosophila p53 binds a damage response element at the reaper locus. Cell 101, 103-113.
6. Brodsky, M. H., Weinert, B. T., Tsang, G., Rong, Y. S., McGinnis, N. M., Golic, K. G., Rio, D. C. and Rubin, G. M. (2004). Drosophila melanogaster MNK/Chk2 and p53 regulate multiple DNA repair and apoptotic pathways following DNA damage. Mol. Cell. Biol. 24, 1219-1231. (Pubitemid 38112184)
7. Carmichael, J., Mitchell, J. B., DeGraff, W. G., Gamson, J., Gazdar, A. F., Johnson, B. E., Glatstein, E. and Minna, J. D. (1988). Chemosensitivity testing of human lung cancer cell lines using the MTT assay. Br. J. Cancer 57, 540-547.
8. Chastagner, P., Merlin, J. L., Marchal, C., Hoffstetter, S., Barberi-Heyob, M., Vassal, G. and Duprez, A. (2000). In vivo potentiation of radiation response by topotecan in human rhabdomyosarcoma xenografted into nude mice. Clin. Cancer Res. 6, 3327-3333. (Pubitemid 30637764)
9. Chou, T. C. and Talalay, P. (1983). Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol. Sci. 4, 450-454.
10. Chou, T. C. and Talalay, P. (1987). Applications of the median-effect principle for the assessment of low-dose risk of carcinogens and for the quantitation of synergism and antagonism of chemotherapeutic agents. In Bristol-Myers Symposium series: New Avenues in Developmental Cancer Chemotherapy (ed. K. R. Harrap and T. A. Connors) New York: Academic Press.
11. Ciuffreda, L., Di Sanza, C., Incani, U. C. and Milella, M. (2010). The mTOR pathway: a new target in cancer therapy. Curr. Cancer Drug Targets 10, 484-495.
12. Dancey, J. (2010). mTOR signaling and drug development in cancer. Nat. Rev. Clin. Oncol. 7, 209-219.
13. Dederick, M. M., Nevinny, H. B., Hall, T. C. and Potee, K. G. (1963). Preliminary report on human toxicity study of streptovitacin A. Cancer Chemother. Rep. 27, 81-86.
14. Delta, B. G., Pinkel, D., Magtibay, L. and Hubbard, J. (1961). Streptovitacin A in children with cancer. Cancer Chemother. Rep. 11, 45-49.
15. Dolma, S., Lessnick, S. L., Hahn, W. C. and Stockwell, B. R. (2003). Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell 3, 285-296. (Pubitemid 37443883)
16. Edwards, A., Gladstone, M., Yoon, P., Raben, D., Frederick, B. and Su, T. T. (2011). Combinatorial effect of maytansinol and radiation in Drosophila and human cancer cells. Dis. Model Mech. 4, 496-503.
17. Felicetti, L., Colombo, B. and Baglioni, C. (1966). Inhibition of protein synthesis in reticulocytes by antibiotics. II. The site of action of cycloheximide, streptovitacin A and pactamycin. Biochim. Biophys. Acta 119, 120-129.
18. Field, J. B. (1963). Clinical evaluation of streptovitacin A. Cancer Chemother Rep. 31, 53-59.
19. Fogarty, P., Campbell, S. D., Abu-Shumays, R., Phalle, B. S., Yu, K. R., Uy, G. L., Goldberg, M. L. and Sullivan, W. (1997). The Drosophila grapes gene is related to checkpoint gene chk1/rad27 and is required for late syncytial division fidelity. Curr. Biol. 7, 418-426. (Pubitemid 27274795)
20. Fujiwara, H., Saito, S. Y., Hitotsuyanagi, Y., Takeya, K. and Ohizumi, Y. (2004). RA-VII, a cyclic depsipeptide, changes the conformational structure of actin to cause G2 arrest by the inhibition of cytokinesis. Cancer Lett. 209, 223-229. (Pubitemid 38670492)
21. Gandin, V., Miluzio, A., Barbieri, A. M., Beugnet, A., Kiyokawa, H., Marchisio, P. C. and Biffo, S. (2008). Eukaryotic initiation factor 6 is rate-limiting in translation, growth and transformation. Nature 455, 684-688.
22. Geran, R. I., Greenberg, N. H., Macdonald, M. M., Schumacher, A. M. and Abbott, B. J. (1972). Protocols for screening chemical agents and natural products against animal tumors and other biological systems (3rd Edition). Cancer Chemother. Rep. 3, 1-103.
23. Hall, E. and Giaccia, A. J. (2005). Radiobiology for the Radiologist. Philadelphia, PA: Lippincott Williams & Wilkins.
24. Hennequin, C., Giocanti, N., Balosso, J. and Favaudon, V. (1994). Interaction of ionizing radiation with the topoisomerase I poison camptothecin in growing V-79 and HeLa cells. Cancer Res. 54, 1720-1728.
25. Ilic, N., Utermark, T., Widlund, H. R. and Roberts, T. M. (2011). PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proc. Natl. Acad. Sci. USA 108, E699-E708.
26. Jaklevic, B., Uyetake, L., Lemstra, W., Chang, J., Leary, W., Edwards, A., Vidwans, S., Sibon, O. and Tin Su, T. (2006). Contribution of growth and cell cycle checkpoints to radiation survival in Drosophila. Genetics 174, 1963-1972. (Pubitemid 46011586)
27. Jaklevic, B. R. and Su, T. T. (2004). Relative contribution of DNA repair, cell cycle checkpoints, and cell death to survival after DNA damage in Drosophila larvae. Curr. Biol. 14, 23-32. (Pubitemid 38069972)
28. Jolad, S. D., Hoffmann, J. J., Torrance, S. J., Wiedhopf, R. M., Cole, J. R., Arora, S. K., Bates, R. B., Gargiulo, R. L. and Kriek, G. R. (1977). Bouvardin and deoxybouvardin, antitumor cyclic hexapeptides from Bouvardia ternifolia (Rubiaceae). J. Am. Chem. Soc. 99, 8040-8044. (Pubitemid 8236779)
29. Kohara, H., Tabata, M., Kiura, K., Ueoka, H., Kawata, K., Chikamori, M., Aoe, K., Chikamori, K., Matsushita, A. and Harada, M. (2002). Synergistic effects of topoisomerase I inhibitor, 7-ethyl-10-hydroxycamptothecin, and irradiation in a cisplatin-resistant human small cell lung cancer cell line. Clin. Cancer Res. 8, 287-292. (Pubitemid 34101490)
30. Lamond, J. P., Mehta, M. P. and Boothman, D. A. (1996a). The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and radiation. J. Neurooncol. 30, 1-6. (Pubitemid 26265764)
31. Lamond, J. P., Wang, M., Kinsella, T. J. and Boothman, D. A. (1996b). Concentration and timing dependence of lethality enhancement between topotecan, a topoisomerase I inhibitor, and ionizing radiation. Int. J. Radiat. Oncol. Biol. Phys. 36, 361-368. (Pubitemid 26359462)
32. Lamond, J. P., Wang, M., Kinsella, T. J. and Boothman, D. A. (1996c). Radiation lethality enhancement with 9-aminocamptothecin: comparison to other topoisomerase I inhibitors. Int. J. Radiat. Oncol. Biol. Phys. 36, 369-376. (Pubitemid 26359463)
33. Lee, M., Draoui, M., Zia, F., Gazdar, A., Oie, H., Bepler, G., Bellot, F., Tarr, C., Kris, R. and Moody, T. W. (1992). Epidermal growth factor receptor monoclonal antibodies inhibit the growth of lung cancer cell lines. J. Natl. Cancer Inst. Monogr. 13, 117-123.
34. Marchesini, R., Colombo, A., Caserini, C., Perego, P., Supino, R., Capranico, G., Tronconi, M. and Zunino, F. (1996). Interaction of ionizing radiation with topotecan in two human tumor cell lines. Int. J. Cancer 66, 342-346. (Pubitemid 26166196)
35. Menzel, D. H. (1960). Fundamental formulas for physics. Nineola, NY: Dover Publications, Inc.
36. Robert, F., Carrier, M., Rawe, S., Chen, S., Lowe, S. and Pelletier, J. (2009). Altering chemosensitivity by modulating translation elongation. PLoS ONE 4, e5428.
37. Rong, Y. S., Titen, S. W., Xie, H. B., Golic, M. M., Bastiani, M., Bandyopadhyay, P., Olivera, B. M., Brodsky, M., Rubin, G. M. and Golic, K. G. (2002). Targeted mutagenesis by homologous recombination in D. melanogaster. Genes Dev. 16, 1568-1581. (Pubitemid 34686337)
38. Ruggero, D., Montanaro, L., Ma, L., Xu, W., Londei, P., Cordon-Cardo, C. and Pandolfi, P. P. (2004). The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat. Med. 10, 484-486. (Pubitemid 38667906)
39. Silvera, D., Arju, R., Darvishian, F., Levine, P. H., Zolfaghari, L., Goldberg, J., Hochman, T., Formenti, S. C. and Schneider, R. J. (2009). Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer. Nat. Cell. Biol. 11, 903-908.
40. Silvera, D., Formenti, S. C. and Schneider, R. J. (2010). Translational control in cancer. Nat. Rev. Cancer 10, 254-266.
41. SirDeshpande, B. V. and Toogood, P. L. (1995). Mechanism of protein synthesis inhibition by didemnin B in vitro. Biochemistry 34, 9177-9184.
42. Tobey, R. A., Orlicky, D. J., Deaven, L. L., Rall, L. B. and Kissane, R. J. (1978). Effects of Bouvardin (NSC 259968), a cyclic hexapeptide from Bouvardia ternifolia, on the progression capacity of cultured Chinese hamster. Cancer Res. 38, 4415-4421. (Pubitemid 9065409)
43. Zalacain, M., Zaera, E., Vazquez, D. and Jimenez, A. (1982). The mode of action of the antitumor drug bouvardin, an inhibitor of protein synthesis in eukaryotic cells. FEBS Lett. 148, 95-97. (Pubitemid 13225241)
44. Zhao, L., Wientjes, M. G. and Au, J. L. (2004). Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin. Cancer Res. 10, 7994-8004. (Pubitemid 39587541)